Description:
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of
lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are
refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma
(NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance
status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel
and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status,
quality of life, and survival.
Title
- Brief Title: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
- Official Title: A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Clinical Trial IDs
- ORG STUDY ID:
017006
- NCT ID:
NCT03483103
Conditions
- Lymphoma, Non-Hodgkin
- Lymphoma, Nonhodgkin
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
Interventions
Drug | Synonyms | Arms |
---|
lisocabtagene maraleucel | JCAR017, liso-cel | Treatment |
Purpose
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of
lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are
refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma
(NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance
status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel
and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status,
quality of life, and survival.
Trial Arms
Name | Type | Description | Interventions |
---|
Treatment | Experimental | Lisocabtagene maraleucel at a dose of 100×10^6 CAR+ T cells (50×10^6 CD8+ CAR+ T cells and 50×10^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy). | |
Eligibility Criteria
Inclusion Criteria:
- Confirmation of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma of the
following histology at relapse: diffuse large B-cell lymphoma (DLBCL), not otherwise
specified (NOS; de novo or transformed follicular lymphoma [tFL]), high-grade B-cell
lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology
(double/triple hit lymphoma [DHL/THL]), and follicular lymphoma Grade 3B per WHO 2016
classification
- Previous treatment must include treatment with a single line of chemoimmunotherapy
containing an anthracycline and a CD20-targeted agent
- Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic
stem cell transplant (based on age, performance status and/or comorbidities) while
also having adequate organ function for CAR T cell treatment.
- Positron emission tomography (PET)-positive disease
- Histological confirmation of diagnosis at last relapse. Enough tumor material must be
available for central confirmation of diagnosis, otherwise a new tumor biopsy is
mandated.
- ECOG performance status of 0, or 1, or 2
- Adequate vascular access for leukapheresis procedure (either peripheral line or
surgically-placed line)
- Subjects must agree to use appropriate contraception
- Subjects must agree to not donate blood, organs, semen, and egg cells for usage in
other individuals for at least 1 year following lymphodepleting chemotherapy
Exclusion Criteria:
- Subjects with central nervous system (CNS)-only involvement by malignancy (note:
subjects with secondary CNS involvement are allowed on study)
- History of another primary malignancy that has not been in remission for at least 2
years.
- Previous treatment with CD19-targeted therapy, with the exception of prior
lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment
- Active hepatitis B or hepatitis C infection at the time of screening
- History of or active human immunodeficiency virus (HIV) infection at the time of
screening
- Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate
antibiotics or other treatment at the time of leukapheresis or lisocabtagene
maraleucel administration
- History of any one of the following cardiovascular conditions within the past 6
months: Class III or IV heart failure as defined by the New York Heart Association,
cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other
clinically significant cardiac disease
- History or presence of clinically relevant CNS pathology
- Pregnant or nursing women
- Subject does not meet protocol-specified washout periods for prior treatments
- Prior hematopoietic stem cell transplant
- Progressive vascular tumor invasion, thrombosis, or embolism
- Venous thrombosis or embolism not managed on stable regimen of anticoagulation
- Uncontrolled medical, psychological, familial, sociological, or geographical
conditions
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Antitumor activity |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Overall response rate (complete response + partial response) based on "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" |
Secondary Outcome Measures
Measure: | Adverse events |
Time Frame: | 90 days |
Safety Issue: | |
Description: | Proportion of subjects experiencing adverse events |
Measure: | Laboratory abnormalities |
Time Frame: | 90 days |
Safety Issue: | |
Description: | Proportion of subjects experiencing laboratory abnormalities |
Measure: | Antitumor activity |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Complete response rate based on "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" |
Measure: | Antitumor activity |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Duration of response |
Measure: | Maximum concentration (Cmax) of lisocabtagene maraleucel in blood |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Maximum concentration of lisocabtagene maraleucel in blood |
Measure: | Time of the maximum concentration (Tmax) of lisocabtagene maraleucel in blood |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Time of the maximum concentration of lisocabtagene maraleucel in blood |
Measure: | Area under the curve of (AUC) lisocabtagene maraleucel concentration in blood |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Area under the curve of lisocabtagene maraleucel in blood |
Measure: | Progression-free survival |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Progression-free survival |
Measure: | Event-free survival |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Event-free survival |
Measure: | Overall survival |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Overall survival |
Measure: | Health-related quality of life and health economics and outcomes research |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is a validated quality of life measure applicable to subjects with any cancer diagnosis. It is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. A 10 point change in the scoring is considered to be a meaningful change in HRQoL. |
Measure: | Health-related quality of life and health economics and outcomes research |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | The EuroQol-5D (EQ-5D) is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). The VAS rating scale is a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. |
Measure: | Health-related quality of life and health economics and outcomes research |
Time Frame: | Through month 24 |
Safety Issue: | |
Description: | The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. Only the LYM subscale will be administered in this study. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale. |
Measure: | Health-related quality of life and health economics and outcomes research |
Time Frame: | Through Month 24 |
Safety Issue: | |
Description: | Numbers of intensive care unit inpatient days and non-ICU inpatient days and reasons for hospitalization |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Juno Therapeutics, a Subsidiary of Celgene |
Trial Keywords
- JCAR017
- lisocabtagene maraleucel
- NHL
- chimeric antigen receptor
- CAR
- CAR T cell
- autologous T cell therapy
- immunotherapy
- cell therapy
- liso-cel
Last Updated
February 8, 2021